I am a board-certified oncologist and hematologist, and work as part of a multidisciplinary team caring for patients with hematologic disorders. I have a special interest and expertise in treating patients with disorders that arise in white blood cells called plasma cells, including multiple myeloma and light chain (AL) amyloidosis.
My research focuses on new treatment approaches for plasma cell disorders. Along with colleagues here, I am testing targeted therapies, immunomodulatory agents, and stem cell transplantation to arrive at more-effective and less-toxic regimens for these diseases.
Very effective novel agents have recently become available for plasma cell disorders, but it is not clear if these are more effective than stem cell transplantation for patients early in the course of their disease. To help answer that question, I am co-leading a study comparing the effectiveness of an immunomodulatory agent (lenalidomide) with that of high-dose therapy and stem cell transplantation. I am also leading a trial to determine the most effective post-stem cell transplant therapy. As the principal investigator of an ongoing trial using a risk-adapted approach to stem cell transplant followed by novel agents in AL amyloidosis, I have had the opportunity to present exciting results demonstrating significant activity and low toxicity with this approach.
For patients whose plasma cell disorder has relapsed, I am investigating novel agents alone and in combinations. Some patients with multiple myeloma and plasma cell disorders do poorly despite treatment. I am collaborating with colleagues here in efforts to develop safer and more-effective donor-derived (allogeneic) hematopoietic stem cell transplantation options using T-cell-depleted grafts, a strategy pioneered at Memorial Sloan Kettering. In order to improve accessibility to treatment and the quality of life of our patients, I am also helping to develop outpatient transplant strategies using state-of-the-art technology (Tele-Health monitoring).
I have also enjoyed mentoring students from the college level through the post-graduate level.
- Clinical Expertise: Hematologic Malignancies with a focus on plasma cell dyscrasias including multiple myeloma, light chain amyloidosis, and plasmacytomas.
- Languages Spoken: English
- Education: MD, Upstate Medical University
- Residencies: Internal Medicine - University of Colorado Health Sciences Center
- Fellowships: Hematology/Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Heather J. Landau
- A Phase I/IIA Study of Carfilzomib plus High-Dose Melphalan Before Autologous Stem Cell Transplant in Patients with Multiple Myeloma
- A Phase IIB Study of NEOD001 versus Placebo to Treat Light Chain Amyloidosis in Previously Treated Patients with Impaired Heart Function
- A Phase III Study of Dexamethasone plus Ixazomib (MLN9708) or Standard Therapy in Patients with Recurrent or Persistent Systemic Light Chain Amyloidosis
- A Phase III Study of Standard Chemotherapy with or without NEOD001 Patients with Newly Diagnosed Light Chain Amyloidosis
- A Study of Captisol-Enabled Melphalan in Patients with Multiple Myeloma and Light Chain Amyloidosis Receiving an Autologous Stem Cell Transplant
- Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma
Clinical Trials Co-Investigated by Heather J. Landau
- A Phase II Study of Bortezomib/Dexamethasone Followed by Lenalidomide in Nonresponders as Initial Treatment for Multiple Myeloma
- A Phase III Study of Lenalidomide, Bortezomib, and Dexamethasone Combination Treatment with or without Peripheral Stem Cell Transplantation in the Initial Management of Multiple Myeloma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more